-+ 0.00%
-+ 0.00%
-+ 0.00%

Q32 Bio names José Trevejo chief medical officer

PUBT·09/14/2026 10:59:16
Listen to the news
Q32 Bio names José Trevejo chief medical officer
  • Q32 Bio named José Trevejo as chief medical officer.
  • Trevejo was chief medical officer and head of clinical pipeline strategy at Enveda Therapeutics.
  • Earlier roles include chief medical officer at Tarsus Pharmaceuticals, chief development officer at Rocket Pharmaceuticals, chief executive officer at SmartPharm Therapeutics.
  • Ellie Hershberger appointed chief development officer.
  • Hershberger previously served as chief development officer at Adagio Therapeutics, now Invivyd, leading its lead monoclonal antibody into Phase 3.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609140659PR_NEWS_USPR_____NE46374) on September 14, 2026, and is solely responsible for the information contained therein.